...
首页> 外文期刊>Orthopaedic Journal of Sports Medicine >Efficacy and Safety of an Etofenamate Medicated Plaster for Acute Ankle Sprain: A Randomized Controlled Trial
【24h】

Efficacy and Safety of an Etofenamate Medicated Plaster for Acute Ankle Sprain: A Randomized Controlled Trial

机译:急性踝关节扭伤的Etofenamate药膏的功效和安全性:随机对照试验

获取原文

摘要

Background: The favorable benefit-risk profile of topical nonsteroidal anti-inflammatory drugs (NSAIDs) makes them a preferred treatment for pain relief in soft tissue injuries. Purpose: To assess the efficacy and safety of a novel etofenamate 70-mg medicated plaster in patients with acute uncomplicated ankle sprain. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: Patients with grade 1 or 2 ankle sprain of recent onset were randomized to etofenamate or placebo plasters (1:1) applied twice daily for 7 days. Clinical assessments, including ankle pain on movement (POM) in mm on a 100-mm visual analog scale (VAS), were made at predefined intervals during the treatment period. Results: In total, 156 male or female adult patients (mean age, 35.3 ± 11.8 years) were enrolled. The fall in VAS values for POM from baseline to 72 hours was markedly in favor of the etofenamate plaster, with respective reductions of 52.7% and 24.0% for active and placebo plasters (least squares mean treatment difference, 22.1 mm; P value for analysis of covariance & .0001). Similar clinically relevant differences between etofenamate and placebo were seen for POM at the 48-, 96-, and 168-hour visits ( P & .0001). These differences between etofenamate and placebo plasters were reflected in area under the curve for POM, pain at rest, and ankle swelling measured at various time points during the 7 days. Time taken to achieve a meaningful (30%) and optimal (50%) reduction of POM was significantly shorter in the etofenamate group. The responder rate (proportion of patients with at least 50% pain reduction at 72 hours) was 52.5% for the etofenamate plaster and 7.7% for the placebo. A significantly greater proportion of patients randomized to etofenamate rated their progress and/or the treatment as “good” or “very good.” The medicated plasters adhered well over the 12-hour dosing period and were very well-tolerated. Conclusion: With respect to the investigated indication, uncomplicated ankle sprain, the etofenamate plaster has therapeutic efficacy that is similar to that for the best available topical NSAID formulations.
机译:背景:局部非甾体抗炎药(NSAIDs)的有利益处风险概况使它们成为软组织损伤中疼痛缓解的优选治疗方法。目的:评估新型Etofenamate 70-mg药物膏药的疗效和安全性在急性松软的踝扭伤患者中。研究设计:随机对照试验;证据水平,1.方法:近期发病率1或2级踝关节扭伤的患者随机分配给EtofeNamate或安慰剂(1:1)每天两次施用7天。在治疗期间,在预定的间隔下,在100mm视觉模拟量表(VAS)上,在MM中的临床评估(包括MM)的踝关节疼痛(POM)。结果:共有156例男性或女性成年患者(平均年龄,35.3±11.8岁)。从基线到72小时的POM的VAS值下降显着有利于Etofenamate石膏,各自的减少52.7%和24.0%的活性和安慰剂(最小二乘性平均处理差异,22.1mm; P值分析协方差& .0001)。在48-,96-和168小时访问(P& .0001)的POM中看到了Etofenamate和安慰剂之间的类似临床相关差异(P& .0001)。将Etofenamate和安慰剂塑料之间的这些差异反映在POM曲线下的区域,静止疼痛,并且在7天内在各个时间点测量踝关节肿胀。在Etofenate组中,达到有意义(30%)和最佳(50%)的最佳(50%)的时间越差明显短。 Etofenamate石膏膏的响应率(至少50%疼痛减少至少50%的疼痛患者的比例为52.5%,安慰剂为7.7%。随机患者的患者比例大幅增加了它们的进展和/或治疗作为“良好”或“非常好”的进展。药物膏药粘附在12小时给药时期,并且非常耐受。结论:关于调查的指示,简单的踝扭伤,Etofenamate石膏具有治疗效果,其类似于最佳可用局部NSAID配方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号